Targeted therapies: summary clinical trials working group

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Defining treatment-susceptible or -resistant populations of patients with cancer through the use of genetically defined biomarkers has revolutionized cancer care in recent years for some disease/patient groups. Research continues to show that histologically defined diseases are diverse in their expression of unique mutations or other genetic alterations, however, which presents opportunities fo...

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the br...

A national cancer clinical trials system for targeted therapies.

Today, modern technologies in genomics, biomarker detection, and molecular imaging are providing information that will enable physicians to select appropriate treatments for individual cancer patients from among more than 800 new experimental drugs and antibodies that target the products of the aberrant genes that can cause cancer. At this promising time in cancer research, the U.S. National Ca...

Alternate Scenarios Working Group Summary

Heavy flavours: working group summary

Production and fragmentation of heavy quarks is one of the most dynamical fields of research in QCD precision tests. There is an active interplay between experimental analysis and theoretical developments in this area. The aim of the working group was to discuss the relevant experimental and theoretical results that became available or updated since the previous DIS workshop in 2008. They are s...